Clinical Trials Using Tasquinimod

Clinical trials are research studies that involve people. The clinical trials on this list are studying Tasquinimod. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trial 1 of 1
  • Tasquinimod Alone and in Combination with Standard Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma

    This phase I trial is to find out the best dose, possible benefits and / or side effects of tasquinimod alone and in combination with standard therapy in treating multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Tasquinimod may work by blocking the action of S100A9, a protein produced by other cells in the bone marrow when they are stimulated by myeloma cells. S100A9 may allow myeloma cells to survive and grow. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving tasquinimod alone or in combination with standard therapy may be effective in treating patients with multiple myeloma.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania